Regenerative medicine company Histogen has received a $2 million grant to help fund a clinical trial for knee cartilage regeneration.

Richmond, Va.-based VCU Health spine surgeon Rick Placide, MD, implanted the first Signafuse strips in a patient during a posterolateral lumbar fusion, according to a Sept. 2 news release.

A number of emerging biologic technologies are currently being evaluated and launched in the spine field. Here are six key developments in the past month:

Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.

Orthobiologics company Royal Biologics acquired the Fibrinet system from Vertical Spine Sept. 1.

Biopharmaceutical company DiscGenics has raised $50 million in a Series C funding round, according to an Aug. 25 news release.

The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health to study the use of bone marrow stem cells to delay osteoarthritis in the knee.

The FDA has cleared Genentech's Evrysdi drug for spinal muscular atrophy in adults and children 2 months of age and older, according to an Aug. 10 announcement.

More than 6,000 members have joined the Biologic Association within the first six months of its website launch.

Since the beginning of the year, Becker's Spine Review has reported on eight orthobiologic and regenerative medicine companies that have launched new products, received FDA clearances and demonstrated favorable outcomes in clinical trials:

Orthobiologics company Cerapedics received FDA approval to reduce the number of patients required for its P-15L bone graft clinical trial.

Spinal implant developer Spine Wave has launched its Tempest Allograft Bone Matrix, according to a July 14 news release.

Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant. 

Orthobiologics company Baxter has received FDA clearance July 9 for its Altapore Shape Bioactive Bone Graft for spine surgery, according to Biospace.

Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.

Orthobiologics company Bioventus on June 25 launched its Signafuse bioactive bone graft in a strip format.

Here are four key developments in spinal biologics in the last month:

Biomaterials startup Spiderwort has closed a $3.4 million seed financing round one year after it secured $500,000 in a friends and family funding round, Betakit reports.

Minimally invasive spine therapy company SpineOvations reported favorable results at the midpoint of its DiscSeal clinical trial.

The European Commission recently approved Zolgensma, Novartis' $2.1 million gene therapy drug for spinal muscular atrophy, for infants and children up to 46 pounds.